Looking back on testing & diagnostics services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Labcorp (NYSE:LH) and its peers.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting with RadNet (NASDAQ:RDNT).
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 9.4%. This performance was disheartening since the S&P 500 held its ground.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Quest (NYSE:DGX) and the best and worst performers in the testing & diagnostics services industry.
Over the past six months, Labcorp has been a great trade, beating the S&P 500 by 6.9%. Its stock price has climbed to $255.01, representing a healthy 13.9% increase. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
The research firm noted that post-pandemic utilization rates have remained high, and Labcorp is positioned to capitalize on this trend through its core diagnostics business.
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 9.8% year on year to $3.33 billion. The company’s full-year revenue guidance of $13.97 billion at the midpoint came in 1.4% above analysts’ estimates. Its non-GAAP profit of $3.45 per share was 1.7% above analysts’ consensus estimates.
Labcorp's Q4 EPS of $3.45 topped estimates, with sales rising 9.8% to $3.33 billion. 2025 guidance points to continued growth in diagnostics and biopharma.
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing services.
